Correction: The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden
-
* Corresponding author: Solbritt Rantapää-Dahlqvist solbritt.rantapaa.dahlqvist@medicin.umu.se
1 Department of Rheumatology, University Hospital, SE-901 85 Umeå, Sweden
2 Department of Transfusion Medicine, University Hospital, SE-901 85 Umeå, Sweden
Arthritis Research & Therapy 2007, 9:403 doi:10.1186/ar2312
The electronic version of this article is the complete one and can be found online at: http://arthritis-research.com/content/9/5/403
| Published: | 25 October 2007 |
© 2007 BioMed Central Ltd
Correction
After publication of our recent article [1], we noticed an error in Table 6 'Relative risk for developing rheumatoid arthritis in patients, stratified for anti-cyclic citrullinated peptide (anti-CCP) antibodies'.
Under the heading of 'Anti-CCP antibody-positive', the first line should read 'HLA-shared epitope-negative', and the second line should read 'HLA-shared epitope-positive'. Similarly, under the heading 'Anti-CCP antibody-negative', the first line should read 'HLA-shared epitope-negative' and the second line should read 'HLA-shared epitope-positive'.
The correct table is given here as Table 1 (a corrected version of Table 6 [1]).
Table 1. Relative risk for developing rheumatoid arthritis in patients, stratified for anti-cyclic citrullinated peptide (anti-CCP) antibodies
References
-
Kokkonen H, Johansson M, Innala L, Jidell E, Rantapää-Dahlqvist S: The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden.
Arthritis Res Ther 2007, 9:R56. PubMed Abstract | BioMed Central Full Text